LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 403

Search options

  1. Article ; Online: Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer-Reply.

    Pinato, David J / Newsom-Davis, Thomas / Bower, Mark

    JAMA oncology

    2020  Volume 6, Issue 4, Page(s) 587–588

    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Humans ; Immune Checkpoint Inhibitors ; Neoplasms/drug therapy ; Nivolumab/therapeutic use
    Chemical Substances Anti-Bacterial Agents ; Immune Checkpoint Inhibitors ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2020-03-05
    Publishing country United States
    Document type Letter ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2019.6868
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Regression of Paraneoplastic Rash after Lung Cancer Chemotherapy.

    Pinato, David J / Newsom-Davis, Thomas

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2017  Volume 13, Issue 1, Page(s) 139–140

    MeSH term(s) Exanthema/etiology ; Exanthema/pathology ; Humans ; Lung Neoplasms/complications ; Lung Neoplasms/drug therapy ; Male ; Middle Aged ; Paraneoplastic Syndromes/etiology ; Paraneoplastic Syndromes/pathology
    Language English
    Publishing date 2017-10-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2017.09.1967
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.

    Neal, Joel / Pavlakis, Nick / Kim, Sang-We / Goto, Yasushi / Lim, Sun Min / Mountzios, Giannis / Fountzilas, Elena / Mochalova, Anastasia / Christoph, Daniel C / Bearz, Alessandra / Quantin, Xavier / Palmero, Ramon / Antic, Vladan / Chun, Elaine / Edubilli, Tirupathi Rao / Lin, Ya-Chen / Huseni, Mahrukh / Ballinger, Marcus / Graupner, Vilma /
    Curran, Dominic / Vervaet, Piet / Newsom-Davis, Thomas

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2024  , Page(s) JCO2302166

    Abstract: Purpose: Although checkpoint inhibitors have improved first-line treatment for non-small cell lung cancer (NSCLC), a therapeutic need remains for patients whose disease does not respond or who experience disease progression after anti-PD-L1/PD-1 ... ...

    Abstract Purpose: Although checkpoint inhibitors have improved first-line treatment for non-small cell lung cancer (NSCLC), a therapeutic need remains for patients whose disease does not respond or who experience disease progression after anti-PD-L1/PD-1 immunotherapy. CONTACT-01 (ClinicalTrials.gov identifier: NCT04471428) evaluated atezolizumab plus cabozantinib versus docetaxel in patients with metastatic NSCLC who developed disease progression after concurrent or sequential treatment with anti-PD-L1/PD-1 and platinum-containing chemotherapy.
    Methods: This multicenter, open-label, phase III trial randomly assigned patients 1:1 to atezolizumab 1,200 mg intravenously once every 3 weeks (q3w) plus cabozantinib 40 mg orally once daily or docetaxel 75 mg/m
    Results: One hundred eighty-six patients were assigned atezolizumab plus cabozantinib, and 180 docetaxel. Minimum OS follow-up was 10.9 months. Median OS was 10.7 months (95% CI, 8.8 to 12.3) with atezolizumab plus cabozantinib and 10.5 months (95% CI, 8.6 to 13.0) with docetaxel (stratified hazard ratio [HR], 0.88 [95% CI, 0.68 to 1.16];
    Conclusion: Atezolizumab plus cabozantinib after disease progression following anti-PD-L1/PD-1 immunotherapy and platinum-containing chemotherapy for metastatic NSCLC did not improve OS compared with docetaxel. Safety was consistent with known profiles of these agents.
    Language English
    Publishing date 2024-03-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.23.02166
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Association of primary and community care services with emergency visits and hospital admissions at the end of life in people with cancer: a retrospective cohort study.

    Leniz, Javiera / Henson, Lesley A / Potter, Jean / Gao, Wei / Newsom-Davis, Tom / Ul-Haq, Zia / Lucas, Amanda / Higginson, Irene J / Sleeman, Katherine E

    BMJ open

    2022  Volume 12, Issue 2, Page(s) e054281

    Abstract: Objective: To examine the association between primary and community care use and measures of acute hospital use in people with cancer at the end of life.: Design: Retrospective cohort study.: Setting: We used Discover, a linked administrative and ... ...

    Abstract Objective: To examine the association between primary and community care use and measures of acute hospital use in people with cancer at the end of life.
    Design: Retrospective cohort study.
    Setting: We used Discover, a linked administrative and clinical data set from general practices, community and hospital records in North West London (UK).
    Participants: People registered in general practices, with a diagnosis of cancer who died between 2016 and 2019.
    Primary and secondary outcome measures: ≥3 hospital admissions during the last 90 days, ≥1 admissions in the last 30 days and ≥1 emergency department (ED) visit in the last 2 weeks of life.
    Results: Of 3581 people, 490 (13.7%) had ≥3 admissions in last 90 days, 1640 (45.8%) had ≥1 admission in the last 30 days, 1042 (28.6%) had ≥1 ED visits in the last 2 weeks; 1069 (29.9%) had more than one of these indicators. Contacts with community nurses in the last 3 months (≥13 vs <4) were associated with fewer admissions in the last 30 days (risk ratio (RR) 0.88, 95% CI 0.90 to 0.98) and ED visits in the last 2 weeks of life (RR 0.79, 95% CI 0.68 to 0.92). Contacts with general practitioners in the last 3 months (≥11 vs <4) was associated with higher risk of ≥3 admissions in the last 90 days (RR 1.63, 95% CI 1.33 to 1.99) and ED visits in the last 2 weeks of life (RR 1.27, 95% CI 1.10 to 1.47).
    Conclusions: Expanding community nursing could reduce acute hospital use at the end of life and improve quality of care.
    MeSH term(s) Death ; Emergency Service, Hospital ; Hospitalization ; Hospitals ; Humans ; Neoplasms/therapy ; Palliative Care ; Retrospective Studies
    Language English
    Publishing date 2022-02-23
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2599832-8
    ISSN 2044-6055 ; 2044-6055
    ISSN (online) 2044-6055
    ISSN 2044-6055
    DOI 10.1136/bmjopen-2021-054281
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot.

    Beard, Chloe / Rogers, Chris A / Fleming, Leah / Conibear, John / Evison, Matthew / Newsom-Davis, Thomas / Barwick, Tara / Mills, Nicola / Stokes, Elizabeth A / De Sousa, Paulo / Batchelor, Tim / Rawlinson, Janette / Baos, Sarah / Harris, Rosie / Lim, Eric

    BMJ open

    2023  Volume 13, Issue 12, Page(s) e081650

    Abstract: Introduction: Lung cancer is the most common cause of cancer death worldwide and most patients present with extensive disease. One-year survival is improving but remains low (37%) despite novel systemic anti-cancer treatments forming the current ... ...

    Abstract Introduction: Lung cancer is the most common cause of cancer death worldwide and most patients present with extensive disease. One-year survival is improving but remains low (37%) despite novel systemic anti-cancer treatments forming the current standard of care. Although new therapies improve survival, most patients have residual disease after treatment, and little is known on how best to manage it. Therefore, residual disease management varies across the UK, with some patients receiving only maintenance systemic anti-cancer treatment while others receive local consolidative treatment (LCT), alongside maintenance systemic anti-cancer treatment. LCT can be a combination of surgery, radiotherapy and/or ablation to remove all remaining cancer within the lung and throughout the body. This is intensive, expensive and impacts quality of life, but we do not know if it results in better survival, nor the extent of impact on quality of life and what the cost might be for healthcare providers. The RAMON study (RAdical Management Of Advanced Non-small cell lung cancer) will evaluate the acceptability, effectiveness and cost-effectiveness of LCT versus no LCT after first-line systemic treatment for advanced lung cancer.
    Methods and analysis: RAMON is a pragmatic open multicentre, parallel group, superiority randomised controlled trial. We aim to recruit 244 patients aged 18 years and over with advanced non-small-cell lung cancer from 40 UK NHS hospitals. Participants will be randomised in a 1:1 ratio to receive LCT alongside maintenance treatment, or maintenance treatment alone. LCT will be tailored to each patient's specific disease sites. Participants will be followed up for a minimum of 2 years. The primary outcome is overall survival from randomisation.
    Ethics and dissemination: The West of Scotland Research Ethics Committee (22/WS/0121) gave ethical approval in August 2022 and the Health Research Authority in September 2022. Participants will provide written informed consent before participating in the study. Findings will be presented at international meetings, in peer-reviewed publications, through patient organisations and notifications to patients.
    Trial registration number: ISRCTN11613852.
    MeSH term(s) Adolescent ; Adult ; Humans ; Carcinoma, Non-Small-Cell Lung/therapy ; Combined Modality Therapy ; Lung ; Lung Neoplasms/therapy ; Multicenter Studies as Topic ; Quality of Life ; Randomized Controlled Trials as Topic
    Language English
    Publishing date 2023-12-10
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2599832-8
    ISSN 2044-6055 ; 2044-6055
    ISSN (online) 2044-6055
    ISSN 2044-6055
    DOI 10.1136/bmjopen-2023-081650
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: The emerging diversity of neuromuscular junction disorders.

    Newsom-Davis, J

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology

    2007  Volume 26, Issue 1, Page(s) 5–10

    Abstract: Research advances over the last 30 years have shown that key transmembrane proteins at the neuromuscular junction are vulnerable to antibody-mediated autoimmune attack These targets are acetylcholine receptors (AChRs) and muscle specific kinase (MuSK) in ...

    Abstract Research advances over the last 30 years have shown that key transmembrane proteins at the neuromuscular junction are vulnerable to antibody-mediated autoimmune attack These targets are acetylcholine receptors (AChRs) and muscle specific kinase (MuSK) in myasthenia gravis, voltage-gated calcium channels (VGCCs) in the Lambert-Eaton myasthenic syndrome (LEMS), and voltage-gated potassium channels (VGKCs) in neuromyotonia. In parallel with these immunological advances, mutations identified in genes encoding pre-synaptic, synaptic and postsynaptic proteins that are crucial to neuromuscular transmission have revealed a similar diversity of congenital myasthenic syndromes (CMS). These discoveries have had a major impact on diagnosis and management.
    MeSH term(s) Female ; Humans ; Infant, Newborn ; Lambert-Eaton Myasthenic Syndrome/physiopathology ; Myasthenia Gravis/genetics ; Myasthenia Gravis/physiopathology ; Myasthenia Gravis, Neonatal/genetics ; Neuromuscular Diseases/classification ; Neuromuscular Diseases/physiopathology ; Neuromuscular Junction/physiopathology ; Pregnancy ; Pregnancy Complications/physiopathology
    Language English
    Publishing date 2007-09-05
    Publishing country Italy
    Document type Journal Article ; Review
    ZDB-ID 2102328-1
    ISSN 1128-2460
    ISSN 1128-2460
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6694: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions.

    Cortellini, A / Barrichello, A P C / Alessi, J V / Ricciuti, B / Vaz, V R / Newsom-Davis, T / Evans, J S / Lamberti, G / Pecci, F / Viola, P / D'Alessio, A / Fulgenzi, C A M / Awad, M M / Pinato, D J

    Annals of oncology : official journal of the European Society for Medical Oncology

    2022  Volume 33, Issue 11, Page(s) 1202–1204

    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Lung Neoplasms/drug therapy ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use
    Chemical Substances pembrolizumab (DPT0O3T46P) ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological
    Language English
    Publishing date 2022-08-08
    Publishing country England
    Document type Multicenter Study ; Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1016/j.annonc.2022.07.1851
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2862: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer.

    Ardizzoni, Andrea / Azevedo, Sergio / Rubio-Viqueira, Belen / Rodriguez-Abreu, Delvys / Alatorre-Alexander, Jorge / Smit, Hans J M / Yu, Jinming / Syrigos, Konstantinos / Höglander, Elen / Kaul, Monika / Tolson, Jonathan / Hu, Youyou / Vollan, Hans Kristian / Newsom-Davis, Thomas

    Journal for immunotherapy of cancer

    2022  Volume 10, Issue 11

    Abstract: In patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), atezolizumab therapy improves survival with manageable safety. The open-label, single-arm phase III/IV TAIL study (NCT03285763) evaluated atezolizumab ... ...

    Abstract In patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), atezolizumab therapy improves survival with manageable safety. The open-label, single-arm phase III/IV TAIL study (NCT03285763) evaluated atezolizumab monotherapy in patients with previously treated NSCLC, including those with Eastern Cooperative Oncology Group performance status of 2, severe renal impairment, prior anti-programmed death 1 therapy, autoimmune disease, and age ≥75 years. Patients received atezolizumab intravenously (1200 mg) every 3 weeks. At data cut-off for final analysis, the median follow-up was 36.1 (range 0.0-42.3) months. Treatment-related (TR) serious adverse events (SAEs) and TR immune-related adverse events (irAEs) were the coprimary endpoints. Secondary endpoints included overall survival (OS), progression-free survival (PFS), overall response rate, and duration of response. Safety and efficacy in key patient subgroups were also assessed. TR SAEs and TR irAEs occurred in 8.0% and 9.4% of patients, respectively. No new safety signals were documented. In the overall population, median OS and PFS (95% CI) were 11.2 months (8.9 to 12.7) and 2.7 months (2.3 to 2.8), respectively. TAIL showed that atezolizumab has a similar risk-benefit profile in clinically diverse patients with previously treated NSCLC, which may guide treatment decisions for patients generally excluded from pivotal clinical trials.
    MeSH term(s) Humans ; Aged ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Lung Neoplasms/drug therapy ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Progression-Free Survival
    Chemical Substances atezolizumab (52CMI0WC3Y) ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2022-11-30
    Publishing country England
    Document type Editorial
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2022-005581
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Neuromyotonia: a diverse disorder.

    Newsom-Davis, John

    Neurology India

    2006  Volume 54, Issue 4, Page(s) 350

    MeSH term(s) Electromyography ; Humans ; Isaacs Syndrome/etiology ; Isaacs Syndrome/physiopathology ; Isaacs Syndrome/therapy ; Potassium Channels, Voltage-Gated/immunology ; Potassium Channels, Voltage-Gated/physiology
    Chemical Substances Potassium Channels, Voltage-Gated
    Language English
    Publishing date 2006-12
    Publishing country India
    Document type Comment ; Journal Article
    ZDB-ID 415522-1
    ISSN 1998-4022 ; 0028-3886
    ISSN (online) 1998-4022
    ISSN 0028-3886
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 698: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: A message from the Editor.

    Newsom-Davis

    Brain : a journal of neurology

    2001  Volume 124, Issue Pt 1, Page(s) 1

    Language English
    Publishing date 2001-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 80072-7
    ISSN 1460-2156 ; 0006-8950
    ISSN (online) 1460-2156
    ISSN 0006-8950
    DOI 10.1093/brain/124.1.1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.26: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top